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Abstract
Background: The natural triterpenes, erythrodiol and uvaol, exert anti-inflammatory, vasorelaxing and anti-proliferative
effects. Angiotensin II is a well-known profibrotic and proliferative agent that participates in the cardiac remodeling
associated with different pathological situations through the stimulation and proliferation of cardiac fibroblasts. Therefore,
the aim of the study was to investigate the preventive effects of the natural triterpenes erythrodiol and uvaol on the
proliferation and collagen production induced by angiotensin II in cardiac myofibroblasts. Their actions on cardiac
hypertrophy triggered by angiotensin II were also studied.
Methodology/Principal Findings: The effect of erythrodiol and uvaol on angiotensin II-induced proliferation was evaluated
in cardiac myofibroblasts from adult rats in the presence or the absence of the inhibitors of PPAR-c, GW9662 or JNK,
SP600125. The effect on collagen levels induced by angiotensin II was evaluated in cardiac myofibroblasts and mouse heart.
The presence of low doses of both triterpenes reduced the proliferation of cardiac myofibroblasts induced by angiotensin II.
Pretreatment with GW9662 reversed the effect elicited by both triterpenes while SP600125 did not modify it. Both
triterpenes at high doses produced an increase in annexing-V binding in the presence or absence of angiotensin II, which
was reduced by either SP600125 or GW9662. Erythrodiol and uvaol decreased collagen I and galectin 3 levels induced by
angiotensin II in cardiac myofribroblasts. Finally, cardiac hypertrophy, ventricular remodeling, fibrosis, and increases in
myocyte area and brain natriuretic peptide levels observed in angiotensin II-infused mice were reduced in triterpene-treated
animals.
Conclusions/Significance: Erythrodiol and uvaol reduce cardiac hypertrophy and left ventricle remodeling induced by
angiotensin II in mice by diminishing fibrosis and myocyte area. They also modulate growth and survival of cardiac
myofibroblasts. They inhibit the angiotensin II-induced proliferation in a PPAR-c-dependent manner, while at high doses
they activate pathways of programmed cell death that are dependent on JNK and PPAR-c.
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Introduction
Cardiac fibroblasts are one of the major cellular components of
the heart. They play an important role in the maintenance of
structural integrity and normal cardiac function, where both cell-
cell and cell-extracellular matrix interactions are essential [1,2].
They participate in the reparative response of damaged tissue to
wound healing, not only through controlled extracellular matrix
production, but also through proliferation, migration and differ-
entiation into hypersecretory myofibroblasts [3–5]. The acquisi-
tion of smooth-muscle-like properties in fibroblasts is associated
with exacerbation of extracellular matrix production [6], which
can trigger impairment of cardiac function by facilitating reduced
contractibility and arrhythmias, and which then ultimately
contribute to heart failure [7–9]. The activation of cardiac
fibroblasts to myofibroblasts is greatly enhanced in chronic cardiac
diseases and after acute cardiac events [9–11]. This transformation
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is controlled by a variety of stimuli, including growth and
vasoactive factors such as angiotensin II, cytokines and mechanical
stimuli [12].
Angiotensin II plays a central role in the development and
complications of cardiovascular diseases by exerting, among other
types of action, a fibrotic one [13–15]. This participation has been
demonstrated by the effectiveness of drugs that interact with this
system on patients with left ventricular hypertrophy or heart
failure [15]. Its fibrotic action involves the activation not only of
growth factors such as connective tissue growth factor (CTGF) but
also new mediators such as galectin 3, which is associated with
adverse long-term cardiovascular outcomes in patient with heart
failure [16,17].
The Mediterranean diet, in which olive oil is the major source of
dietary fat intake, has been associated with low incidence of
cardiovascular diseases [18,19] and cancer [20–22]. Although
these health benefits have long been attributed to a high content of
monounsaturated fatty acids (oleic acid), a wide variety of minor
components are under evaluation. Among these bioactive
compounds are the triterpenes including the diols, uvaol and
erythrodiol [23]. Many pharmacological properties, including
antiinflammatory, antitumoral and antioxidant activities [24–26],
have been reported for these compounds. In addition, recent
studies have suggested beneficial effects on the cardiovascular
system, since antihypertensive vasodepressor, cardiotonic, and
antidysrhythmic properties have been reported [27–29]. However,
the effect of these compounds on normal cells, especially on
cardiac cells, is unknown. Thus, in the search for novel
pharmacological approaches for the management of cardiovascu-
lar pathologies, the antiproliferative and antifibrotic effects of these
triterpenes are noteworthy. We thus proposed to investigate in vivo
and in vitro the potential benefits of erythrodiol and its isomer, the
ursane diol uvaol, on cardiac effects of angiotensin II. To this end,
we explore their modulatory effects on angiotensin II-induced
proliferation and collagen production in cardiac myofibroblasts as
well as the possible mediators involved. In addition, we explore the
effect of erythrodiol and uvaol on the cardiac hypertrophy induced
by angiotensin II in mice.
Methods and Materials
Ethics Statement
The Animal Care and Use Committee of Universidad
Complutense of Madrid and Universidad de Valladolid approved
all experimental procedures according to guidelines for ethical
care of experimental animals of the European Community.
Animals
Twenty four 8-week-old C57BL/6J mice (Harlan Ibe´rica,
Barcelona, Spain) were randomly divided into 4 groups of 6
animals. Angiotensin II (Sigma) was administered with osmotic
mini-pumps (Alzet model 1002, 1.44 mg Kg21 day21) for 2 weeks.
Some of the animals were treated for the same period with
erythrodiol or uvaol at a dose of (50 mg Kg21 day21) by i.p.
injection. In the control group, mice received vehicle (saline
solution) for 2 weeks. The dosage of angiotensin II, erythrodiol
and uvaol were chosen from previous studies. In the case of
angiotensin II, this dose induced left ventricle hypertrophy and
fibrosis in mice [30]; in the case of both triterpenes, treatment was
able to prevent the development of multiple sclerosis in mice [25].
Isolation of Cardiac Fibroblast
Non-myocytes from adult male Wistar rats (Harlan Ibe´rica,
Barcelona, Spaina) weighing 250–300 g were obtained by
differential centrifugation of cardiac cells released after retrograde
Langendorf perfusion and enzymatic digestion of the hearts, as
previously described [31]. Briefly, rats were anesthetized with
sodium pentobarbital (50 mg/kg) before the heart was removed.
Afterwards, hearts were first perfused for 2–3 min at 36–37uC
with a nominally calcium-free Tyrode solution containing 0.2 mM
EGTA, and then for approximately 3–4 min, with the same
Tyrode solution containing 251 UI of collagenase type II
(Worthington) and 0.1 mM CaCl2. At the end of the perfusion
period, the heart was removed from the Langendorff apparatus
and cut off, chopped into small pieces and gently stirred in a
solution containing 1 mg/ml of bovine serum albumin (BSA,
Sigma). The fibroblasts were collected by centrifugation and
resuspended in DMEM. The homogeneity of these primary
isolates was assessed by immunochemistry using anti-vimentin
(Novocastra Laboratories, Newcastle, UK). Cells in the present
study were used at 2–3 passages. Characterization of the cells using
immunocytochemistry revealed consistent coexpression of vimen-
tin (Figure 1A) and a-smooth muscle cell actin (a-SMA; Figure 1B)
and a consistent coexpression of both antigens (Figure 1C) through
passage 1, indicating that the cells possessed a myofibroblasts
phenotype.
Cell Culture Conditions
The cells were maintained in DMEM medium supplemented
with 10% FBS, 10 mM L-glutamine, 100 U/ml penicillin/
streptomycin, 10 mM, L pyruvate and 2 mM HEPES. The cells
were seeded at a density of 0.56106 cells in a T-175 tissue culture
flask and then grown as monolayer culture. Cells were passaged
with 0.25% trypsin in 0.01% EDTA whenever they became
confluent. All assays in the present study were done at
temperatures of 37uC, 95% sterile air and 5% CO2 in a saturation
humidified incubator.
Cell Proliferation Assay
Cell proliferation was assessed using the CellTiter 96 Non-
Radioactive Cell Proliferation Assay (Promega Corporation,
Madison, WI, USA). Cardiac myofibroblasts were seeded on 96-
well plates (206103cells/well) in DMEM medium and were
allowed to attach for 24–36 hours. Afterwards, cells were switched
to serum-free medium for 24-h. Cells were then treated with
angiotensin II in the presence or absence of different doses of (0.5–
50 mM) erythrodiol or uvaol for 24 hours. Cells were pretreated
with either vehicle or triterpenes for 30 min before the addition of
angiotensin II. The proliferative response was quantified by
adding MTT tetrazolium solution (20 ml/well). After 2–3 hours of
incubation absorbance was measured at 490 nm in a microplate
reader (ASYS Hitech GmbH, Austria). Three different assays were
each performed in quintuplicate.
In some experiments, cells were pretreated for 30 min with
either the selective PPAR-c antagonist (2-chloro-5-nitro-N-phe-
nylbenzamide; GW9662: 1–10 mM), mitogen-activated protein
kinase (MEK) inhibitor (PD98059; 5–50 mM) or stress-activated c-
Jun N-terminal kinase (JNK) inhibitor (SP600125; 5–20 mM).
Analysis of Apoptosis
After a 24-hour treatment with 1 mM of angiotensin II in the
presence or absence of different doses of erythrodiol or uvaol, cells
were used for an Annexin V-PE Apoptosis Assay, as previously
described [23]. Briefly, 16105 cells were resuspended in 0.5 ml
binding buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 2.5 mM
CaCl2, 1 mM MgCl2, 4% BSA), and incubated for 15 min with
2.5 ng/ml Annexin V-PE, followed by flow cytometric analysis
using an EPICS XL cytofluorometer, Beckman-Coulter. In some
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experiments, cardiac myofibroblasts were cultured in the presence
of the inhibitors, PD98059, SP600125, or GW9662 in order to
evaluate the participation of ERK, JNK and PPAR-c pathways in
the apoptotic effect induced by the triterpenes.
Western Blot
Total and nuclear proteins were prepared as previously
described from cell extracts isolated from cardiac myofibroblasts
treated with either 1 mM angiotensin II or vehicle for 12 hours
with or without 5 mM of triterpenes. Proteins were separated by
SDS-PAGED on 10% polyacrylamide gels and transferred to
polyvinylidene difluoride membranes (Hybond-P; Amersham
Biosciences, Piscataway, NJ). Membranes were probed with
primary antibody for a-SMA (Biocare Medical, CA, USA),
PPAR-c (Santa Cruz, Inc, USA), collagen I (AbD Serotec,
Oxford, UK), connective tissue growth factor (CTGF; Torrey
Pines Biolabs Inc, East Orange, NJ) and galectin 3 (Thermo
Scientific, Rockford, IL) followed by incubation with an HRP-
linked secondary antibody. Signals were detected using the ECL
system (Amersham Pharmacia Biotech). Results are expressed as
an n-fold increase over the values of the control group in
densitometric arbitrary units. Phosphorylated ERK1/2 (Cell
Signaling Technology, Inc, New England, USA) and total
ERK1/2 (Zymed Laboratories, CA, USA) protein levels were
analyzed in cell extracts isolated from cardiac myofibroblasts
treated with 1 mM of angiotensin II or vehicle for 15 minutes with
or without different doses of the triterpenes.
Morphological and Histological Evaluation
Hearts were arrested in diastole using KCl before harvesting,
and then dehydrated and embedded in paraffin. Histological
determinations in cardiac tissue were performed in 4 mm-thick
sections. In Masson’s trichrome stained sections, left ventricular
cross sectional area (LVCSA) and left ventricular wall thickness
(LVWT) were measured. Two or three serial sections for each
animal at the midregion area were analysed with a 5X objective
lens under microscopy transmitted light. For cardiomyocyte cross
sectional area, at least 60–80 cardiomyocytes per animal were
measured with a 40X objective lens under microscopy transmitted
ligh. Cardiomyocyte with visible nucleus and intact cellular
membrane were only measured.
Fibrosis was quantified in Picro-sirius red-stained sections. The
area of interstitial fibrosis was identified after excluding the vessel
area from the region of interest, as the ratio of interstitial fibrosis or
collagen deposition to the total tissue area. For each sample, 10 to
15 fields were analyzed with a 40X objective lens under
microscopy transmitted light. Perivascular fibrosis was also
analysed. All measurements were performed blind in an automat-
ed image analysis system (Metamorph 7.0, Molecular Devices
Corporation, USA). Images were calibrated with known stan-
dards. A single researcher unaware of the experimental groups
performed the analysis.
Immunocytochemistry
Cardiac myofibroblasts were fixed in 4% paraformaldehyde for
30 min and permeabilized with 1% Triton62100. Preincubation
was carried out for 30 min in a PBS solution containing 30%
normal horse serum. Cells were then incubated overnight at 4uC
in a solution containing 1/100 anti-vimentin (Novocastra, Leyca
Byosystems, Newcastle, UK) or 1/100 anti-a-SMA monoclonal
antibodies (Oncogene Biocare medical, Concord, CA). After three
washings (5 min each) in PBS, the cells were incubated for 1 h in
fluorescein or Texas red horse anti-mouse IgG (Vectastin Vector)
1/200 in PBS [32]. Nuclei were stained with DAPI (Sigma-
Aldrich, Germany). Negative controls were carried out. Images
were visualized and photographed with a 40X objective in a Leica
DMI 3000 B microscopy.
Figure 1. Representative immunocytochemistry images of
cardiac myofibroblasts examined by fluorescence microscopy.
Vimentin staining (A), a-smooth muscle actin (a-SMA) staining (B) and
vimentin and a-SMA staining merged (C). Magnification 40X. Scale bar:
50 mm.
doi:10.1371/journal.pone.0041545.g001
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Evaluation of Brain Natriuretic Peptide (BNP) by an
Enzyme-Linked Immunosorbent Assay (ELISA)
BNP levels were determined in serum samples by using a mouse
BNP-specific ELISA (RayBiotech, Norcross, GA, USA) according
to the manufacturer’s protocols. Data were processed and
expressed as concentration of BNP/ml of serum samples.
Statistical Analysis
Data are expressed as mean 6 SEM. Cell proliferation data are
expressed as the percentage of the values in control conditions.
Data were analyzed using a one-way analysis of variance, followed
by a Newman-Keuls or Dunnet test to assess specific differences
among doses or control conditions, respectively using GraphPad
Software Inc. (San Diego, CA, USA). The predetermined
significance level was p,0.05.
Results
Erythrodiol and Uvaol Modulate the Proliferative
Response of Angiotensin II
Effects of erythrodiol and uvaol were examined on cardiac
myofibroblasts proliferation induced by angiotensin II. As
previously described, angiotensin II induced a dose-dependent
increase in cardiac myofibroblasts growth (Figure 2A). The dose
inducing the maximal change, 1 mM, was used for all subsequent
experiments. Angiotensin II treatment also triggered, as expected,
a strong and sustained activation/phosphorylation of ERK1/2
(Figure 2B), which play a central role in the regulation of
myofibroblast proliferation. As shown in Figure 2C and D the
presence of the MEK inhibitor PD98059 strongly reduce the
proliferative effect and abrogated ERK phosphorylation and
induced by angiotensin II (1 mM).
The presence of either erythrodiol or uvaol (Figures 2E and 2F
respectively) was able to reduce the angiotensin II-induced
proliferation in a dose-dependent manner. Interestingly, indepen-
dently of the presence or not of angiotensin II, the highest doses of
both triterpenes (25–50 mM) seems to influence cell viability,
because they were able to reduce the number of cells to levels
lower than those of basal conditions. At such doses, both
triterpenes reduced the phosphorylation of ERK1/2 (Figures 2G
and 2H, respectively). No effect on ERK 1/2 phosphorylation was
observed with the lower doses of either triterpene (5–10 mM).
The presence of PD98059 (25 mM) in cells pretreated with
either erythrodiol or uvaol at 5 mM, further reduced the
proliferation induced by angiotensin II (Figures 3A and 3B,
respectively). Next, in order to explore the role of PPAR-c on the
antiproliferative effects of erytrodiol and uvaol, we used the
specific PPAR-c inhibitor, GW9662 (10 mM). As shown in
Figures 3C and 3D, pretreament with the specific PPAR-c
inhibitor, GW9662, reversed the reduction in angiotensin II-
induced proliferation of cardiac myofibroblasts observed in the
presence of either erythrodiol (5 mM) or uvaol (5 mM). In addition,
the reduced nuclear protein levels of PPAR-c observed in
angiotensin II-treated cells were reversed in those pretreated with
both triterpenes (Figure 3E).
Erythrodiol and Uvaol at High doses Induced Apoptosis
of Cardiac Myofibroblasts
To determine whether the anti-proliferative effects of erythro-
diol and uvaol were associated with the beginning of apoptotic
processes in cardiac myofibroblasts, we monitored, as an
apoptotic feature, the appearance of phosphatidylserine on the
cell surface using an annexin-V binding assay. Minimal
differences in annexin V–positive cells, which were not statisti-
cally significant (p.0.05), were found at the lower doses (1–
10 mM) in the erythrodiol- or uvaol-stimulated cells after
24 hours of culture, as compared with unstimulated ones
(Figures 4A and 4B, respectively). Only the highest doses of
either erythrodiol or uvaol (25–50 mM) were able to induce a
significant increase in cells stained positive with annexin V–
phycoerythrin (independently or not of the presence of angio-
tensin II) when compared to the unstimulated cells (p,0.05); this
suggests that these high doses of both triterpenes are able to
induce apoptosis of cardiac myofibroblasts (Figure 4A and 4B,
respectively). As shown in Figures 4C, 4D, 4F, either erythrodiol
or uvaol at the dose of 25 mM (Figures 4D and 4F, respectively)
cause retraction, rounding and shrinking of cardiac myofibro-
blasts and vimentin filament rearrangement; this was not
observed at the dose of 5 mM (Figures 4C and 4E, respectively),
where cells presented an appearance similar to that of control
cells (Figure 1).
To determine if apoptosis of cardiac myofibroblasts was
mediated by the abrogated phosphorylation of ERK 1/2, the
apoptotic response was measured in cells pretreated with the
inhibitor PD98059 either in the presence or absence of angiotensin
II. No differences in the mean fluorescence intensity of annexin V
incorporation were observed in cells exposed to 25 mM of
PD98058, a dose that effectively prevents ERK1/2 phosphoryla-
tion, compared to untreated ones (Figure 4G).
In contrast, triterpene-induced cell death was markedly reversed
by pretreatment with 20 mM of the specific JNK inhibitor,
SP600125 (Figures 5A, and 5B). The same protective effect of
the inhibitor SP600125 was observed when cells were stimulated
simultaneously with the triterpenes and angiotensin II. Cellular
viability in control cardiac myofibroblast was not affected by the
inhibitor at the tested dose. The presence of the p38 inhibitor
SB203580 did not modify the apoptotic response triggered by the
triterpenes (data not shown).
Finally, the role of PPAR-c was evaluated by conducting
annexin-V binding experiments in cells pre-treated with different
doses of the PPAR-c antagonist GW9662. As shown in figures 5C
and 5D, the apoptotic response in erythrodiol- and uvaol-treated
cells was inhibited by the presence of the inhibitor GW9662
(10 mM), suggesting that this response was PPAR-c-dependent.
The inhibitory effect of GW9662 was also observed in cells
exposed simultaneously to triterpene and angiotensin II.
Erythrodiol and Uvaol Abrogate the Fibrotic Effect of
Angiotensin II on Cardiac Myofibroblasts
Angiotensin II at the dose of 1 mM induced an increase in
collagen I synthesis in cardiac myofibroblasts (Figure 6A),
reaching the maximum effect at 12 hours. This production
seems to be independent of CTGF because no changes in protein
expression were observed at the time angiotensin II induced the
maximal synthesis of collagen I (Figure 6B). To determine
whether these triterpenes were able to modify angiotensin II-
induced profibrotic effects, cardiac myofibroblasts were exposed
to erythrodiol (5 mM) or uvaol (5 mM). Their presence (Figure 6C)
was able to reduce collagen I production induced by angiotensin
II (1 mM). However, no changes were observed in cells pretreated
with the triterpenes in absence of angiotensin II (data not shown).
The increase in galectin 3 protein levels induced by angiotensin
II was smaller in the presence of either erythrodiol (5 mM) or
uvaol (5 mM) (Figure 6D). However, no changes were observed in
galectin 3 protein levels in cardiac myofibroblasts pretreated with
the triterpenes in absence of angiotensin II (data not shown).
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Figure 2. Effect of erythrodiol or uvaol on the proliferation and ERK 1/2 phosphorylation induced by angiotensin II. Cardiac
myofibroblasts were stimulated with different doses of angiotensin II (Ang II; A) or with 1 mM of Ang II at different times (B). Cells in the absence or
presence of different concentrations of a specific MEK inhibitor (PD98059; C and D), erythrodiol (ERY; E and G) or uvaol (UVA; F and H). After 24 h of
incubation at 37uC (A, C, E and F), cell proliferation was determined by an MTT assay and expressed as percent of controls (vehicle, v). (B, D, G and H),
after 15 min stimulation, whole cell lysates were extracted and protein phosphorylation was assessed by Western blotting using phospho-ERK and
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Erythrodiol and Uvaol Abrogate the Fibrotic Effect of
Angiotensin II on Mice
In order to verify the potential antifibrotic effect of both
triterpenes in vivo, we explored the effect of the administration
of either erythrodiol or uvaol (50 mg Kg21 day 21) in mice
infused with angiotensin II (1.44 mg Kg21 day 21, 2 weeks). As
expected, angiotensin II led to significant cardiac hypertrophy at
the organ and cellular level which was prevented by triterpenes
treatment. Heart weight, normalized to body weight (HW/BW),
was significantly increased in mice in response to angiotensin II
when compared to vehicle-treated mice (Figure 7A). This
hypertrophy seems to correlate with an increase in both cardiac
myocyte size (Figures 7B, 7C, 7D), interstitial (Figures 8A, 8B,
8C) and perivascular matrix deposition (Figures 8F, 8G, 8H).
These changes can participate in the left ventricle remodeling
induced by angiotensin II since these animals show a higher
LVCSA as well as LVWT as compared with controls
(Figures 9A and 9B, respectively). Treatment with either
erythrodiol or uvaol was able to reduce cardiac hypertrophy
observed in angiotensin II-induced animals (Figures 7B, 7E and
7F, respectively) by decreasing both interstitial (Figures 8A, 8D
and 8E, respectively) and perivascular fibrosis (Figure 8B, 8I
and 8J, respectively). In addition, they also reduce the changes
in both LVCSA and LVWT induced by angiotensin II
(Figures 9A and 9B, respectively).
Next, the serum concentration of the BNP, a biomarker of
cardiac damage, was measured. BNP is a cardiac neurohormone
secreted from the cardiac ventricles as a response to ventricular
volume expansion and pressure overload [33]. BNP levels have
been shown to be elevated in patients with hypertrophic
cardiomyophathy and left ventricular dysfunction, and correlated
to New York Heart Association class as well as prognosis. As
shown in Figure 9C, BNP levels were significantly higher in mice
in response to angiotensin II when compared to vehicle-treated
mice. Treatment with either erythrodiol or uvaol was able to
reduce BNP levels observed in angiotensin II-induced animals
(Figure 9C).
Discussion
The study shows that the natural triterpenes, erythrodiol and
uvaol, modulate some of the cardiac effects of angiotensin II.
Indeed, the proliferation and fibrosis induced by angiotensin II in
cardiac myofibroblasts in vitro was prevented by both triterpenes,
as was the cardiac hypertrophy, left ventricle remodeling and
fibrosis observed in angiotensin II infused animals. These actions
could result in relevant benefits with potential clinical conse-
quences, since activation of the renin-angiotensin system is a
common feature of cardiovascular diseases [15].
Ample data have demonstrated that triterpenes from different
origins exert antiproliferative actions on different tumoral cell lines
[24,34,35]. Indeed, synthetic triterpenoids are found in phase I/II
clinical trials for the treatment of leukemias and solid tumors [36].
The present data showed that erythrodiol and uvaol are also able
to modulate proliferation and survival of non-tumoral cells. At low
doses, both triterpenes were able to reduce angiotensin II-induced
proliferation in cardiac myofibroblasts without affecting cell
integrity and attachment through a PPAR-c dependent pathway.
However, at high doses erythrodiol and uvaol (25–50 mM) reduce
cardiac myofibroblast survival both in the presence and absence of
angiotensin II. Proliferation of cardiac myofibroblasts is an
essential step involved in the reparative response to wound healing
of damaged tissue. However, a large number of these cells, and
especially hypersecretory myofibroblasts, can cause an aberrant
remodeling through increased extracellular matrix deposition that
favours functional alterations. Indeed, both triterpnes were able to
reduce the cardiac remodeling induced by angiotensin II. Thus,
our data suggest that triterpenes – besides exerting antitumoral
actions – can produce beneficial effects on the cardiovascular
system.
In agreement with previous studies [37], Ras/ERK1/2 seems
to be the intracellular signaling pathway involved in the
proliferative effect of angiotensin II in cardiac myofibroblasts.
This is suggested by the fact that angiotensin II induced ERK1/2
phosphorylation, and that the presence of MEK inhibitor
reduced this mitogenic effect. However, the modulation elicited
by both triterpenes seems to be partially independent of ERK1/2
signaling. This assertion is supported by the fact that neither
erythrodiol nor uvaol was able to modify the phosphorylation
induced by angiotensin II at the dose which inhibits proliferation,
which was only abrogated at the highest doses of the triterpenes
(25–50 mM). In addition, the simultaneous presence of the MEK
inhibitor and either erythrodiol or uvaol further reduces the
proliferative activity of angiotensin II. Nevertheless, this inhibi-
tion also appears to be unrelated to their pro-apoptotic actions,
since the pharmacological inhibition of ERK did not trigger any
relevant increase in annexin-V binding in angiotensin II-
stimulated myofibroblasts.
Various actions have been described by triterpenes in a PPAR-
c-dependent manner. It has been shown that some betulinic acid
derivatives, among other triterpenes, act as PPAR-c agonists,
inducing differentiation of adipocytes [33]. Corosolic acid
ameliorates obesity and hepatic steatosis in mice by increasing
PPAR-c expression in white adipose tissue [38]. The synthetic
triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid in-
creases cellular levels of PPAR-c and regulates apoptosis in
leukemic cells via caspase-8 [39]. Therefore, activation of PPAR-
c could be a pathway involved in the triterpene-exerted
modulation of angiotensin II-proliferation. This hypothesis is
confirmed by two facts: first, a specific PPAR-c inhibitor is able
to reverse the reduction induced by erythrodiol and uvaol on
angiotensin II-induced proliferation and second, the reduced
PPAR-c nuclear levels induced by angiotensin II were abrogated
upon treatment with the triterpenes. A modulatory role of
PPAR-c in the effects of angiotensin II in cardiac myofibroblasts
has been previously reported. Administration of the PPAR-c
agonist rosiglitazone has been associated with a reduction in the
proliferative effect induced by angiotensin II in murine cardiac
fibroblasts [40,41]. Likewise, chronic treatment with rosiglitazone
to rats was able to partially prevent the collagen deposition
induced by the infusion of angiotensin II [39]. Therefore, these
data support that triterpenes might modulate the proliferative
effect of angiotensin II in cardiac myofibroblasts by interfering
with its effect on PPAR-c.
A key molecule involved in cell survival is the stress kinase JNK,
which has been found to mediate triterpene apoptosis in different
tumoral cells [42]. Through pharmacological inhibition of JNK
with SP600125, we have demonstrated that this pathway is a key
component of the signalling involved in erythrodiol- and uvaol-
induced apoptotic death in cardiac myofibroblasts. However, the
total ERK antibodies. Membranes always were stained with Ponceau S as a loading control. Representative immunoblots of 3 experiments. Values are
mean 6 SEM of three assays; *p,0.05 vs vehicle (V). {p,0.05 vs either 0 (absence of ERY or UVA) or Ang II.
doi:10.1371/journal.pone.0041545.g002
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Figure 3. Effect of specific inhibitors on the antiproliferative activity of erythrodiol or uvaol in angiotensin II-treated cardiac
myofibroblasts. Cells pretreated for 30 min with the specific inhibitors of either MEK (A and B; PD98059) or PPAR-c (C and D; GW9662) were
stimulated with 1 mM of angiotensin II (Ang II) for 24 hours in the presence of 5 mM of either erythrodiol (ERY; A and C) or uvaol (UVA; B and D).
Proliferation was determined by an MTT assay. Data are expressed as percent of unstimulated cells. Values are mean 6 SEM of three assays. Panel E
represents the effect of either ERY (5 mM) or UVA (5 mM) on nuclear PPAR-c protein levels in Ang II-treated cardiac myofibroblasts. Nuclear proteins
from cells stimulated with 1 mM of Ang II from 12 hours in the presence or absence of the indicated triterpene were analysed by western blotting a
specific antibody against PPAR-c. Representative immunoblots of 4 experiments. Quantification of band intensities was measured by densitometry
and normalized to respective a-tubulin. *p,0.05 vs vehicle. {p,0.05 vs angiotensin II. #p,0.05 vs erythrodiol or uvaol.
doi:10.1371/journal.pone.0041545.g003
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inhibition of JNK pathway does not affect the antiproliferative
response induced by low doses of triterpenes. It thus appears that
JNK activation, while required for triterpene-induced apoptosis, is
dispensable for their antimitogenic actions. We have also observed
that these highest apoptotic doses of triterpenes cause retraction,
rounding and shrinking of cardiac myofibroblasts and amorphous
and condensed pattern. Cytoskeletal elements going to reorgani-
zation is a hallmark of apoptosis [43]. Similarly, we have
previously observed that the apoptosis of astrocytoma induced
by these triterpenes was accompanied by cytoskeletal protein
Figure 4. Efect of erytrodiol and uvaol in cardiac myofibroblasts apoptosis. Cardiac myofibroblast were treated with different doses of
erythrodiol (ERY; A) or uvaol (UVA; B) in the presence or absence of angiotensin II (Ang II, 1 mM). After 24 h of stimulation, cells were labeled with
annexin-V PE and analyzed by flow cytometry. Values are mean 6 SEM of three experiments. *p,0.05 vs cells in the absence of either erythrodiol or
uvaol. Figures C–F show representative immunocytochemistry images of cardiac myofibroblasts treated for 24 hours with erythrodiol (C: 5 mM; D:
25 mM) or uvaol (E: 5 mM; F: 25 mM) examined by fluorescence microscopy. Vimentin staining is shown in green and nuclei staining in blue.
Magnification 40X. Scale bar: 50 mm. Figure G: Effect of a specific inhibitor of MEK (PD9805; 25 mM) on the apoptosis in the presence or absence of
angiotensin II in cardiac myofibroblasts. Cells obtained after PD98059 treatment in the absence of the inhibitor (open black curve) are compared with
cells treated in the presence of the inhibitor (open gray curves). Solid gray curves represent resting control cells.
doi:10.1371/journal.pone.0041545.g004
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rearrangements, as well as an altered expression of CD44, a
molecule which facilitates cell-cell and cell-extracellular matrix
communication [42].
We also found that erythrodiol and uvaol reduce the
production of fibrosis in mice infused with angiotensin II. This
can be a direct effect of triterpenes because a reduction in
collagen I production was observed in triterpene-treated cardiac
myofibroblasts. This thus suggests a modulatory role of these
compounds of the profibrotic effect of angiotensin II. Extracel-
lular matrix accumulation is a common response of the heart to
different insults. However, as we have already mentioned, the
excessive extracellular matrix deposition due to a large number
of myofibroblasts can cause an aberrant remodeling through
increased extracellular matrix deposition that favours functional
alterations, since a reduced flexibility of heart can increase its
filling pressure and contribute to diastolic dysfunction [7]. In fact,
triterpenes were also able to prevent the left ventricular
remodeling induced by angiotensin II in mice. This improvement
was accompanied by a reduction in BNP levels, a biomarker of
cardiac damage that is secreted from the cardiac ventricles as a
response to ventricular volume expansion and pressure overload
[33]. Therefore, these data suggest an improvement in cardiac
Figure 5. Effect of specific inhibitors on the apoptotic activity of erythrodiol or uvaol in cardiac myofibroblasts. Effect of a specific
inhibitor of either JNK (SP600125) or PPAR-c, (GW9662) on the apoptosis induced by either erythrodiol (ERY; 25 mM A and C, respectively) or uvaol
(UVA; 25 mM; B and D, respectively) in the presence or absence of angiotensin II (Ang II; 1 mM) in cardiac myofibroblasts. Representative of 3
experiments. In all panels, cells obtained after triterpene treatment in the absence of the inhibitor (open black curve) are compared with cells treated
in the presence of the inhibitor (open gray curves). Solid gray curves represent control cells.
doi:10.1371/journal.pone.0041545.g005
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Figure 6. Effect of erythrodiol and uvaol on the fibrotic effect of angiotensin II in cardiac myofibroblasts. Time course of angiotensin II
(Ang II; 1 mM)-stimulated collagen I protein production (A). Effect of erythrodiol (ERY; 5 mM) or uvaol (UVA; 5 mM) on CTGF (B), collagen I (C) and
galectin 3 (D) protein expression in angiotensin II-treated cardiac myofibroblasts for 12 hours. Representative immunoblots of 4 experiments. Values
are mean 6 SEM of four assays. *p,0.05 vs vehicle. {p,0.05 vs angiotensin II. Quantification of band intensities was measured by densitometry and
normalized to respective a-tubulin.
doi:10.1371/journal.pone.0041545.g006
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function. Similarly, chronic or acute administration of triterpene-
saponins to rats prevents the cardiac dysfunction and remodeling
induced by diabetes or protects against myocardial ischemia-
reperfusion injury [44,45]. The administration of the triterpene
lupeol also reduced the cardiac alterations associated with
hypercholesterolemia [46]. Therefore, our results are in line
Figure 7. Effect of erythrodiol and uvaol on the hypertrophyc effects of angiotensin II on mice. Mice infused with angiotensin II (Ang II;
1.44 mg Kg21 day 21) were treated with erythrodiol (ERY; 50 mg Kg21 day21) or uvaol (UVA; 50 mg Kg21 day 21) for two weeks. (A) relative heart
weight and (B) cardiac myocyte area. Representative microphotographs of myocardial sections from control (C, CT), angiotensin II-infused animals
treated with vehicle (D), erythrodiol (E), or uvaol (F). Magnification 40X. Samples were stained with Masson’s trichrome technique. Scale bar: 100 mm.
Values are mean 6 SEM of 5–6 animals. *p,0.05 vs control. {p,0.05 vs angiotensin II.
doi:10.1371/journal.pone.0041545.g007
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Figure 8. Effect of erythrodiol and uvaol on the fibrotic effects of angiotensin II on mice.Mice infused with angiotensin II (Ang II; 1.44 mg
Kg21 day21) were treated with erythrodiol (ERY; 50 mg Kg21 day21) or uvaol UVA (50 mg Kg21 day21) for two weeks. Fibrosis was assessed by Picro-
sirius red staining procedure. Interstitial (A) and perivascular (F) collagen quantification. Representative microphotographs of myocardial sections
showing interstitial and perivascular fibrosis from control (B, G), angiotensin II-infused animals treated with vehicle (C, H), erythrodiol (D, I), or uvaol (E,
J). Magnification 40X. Scale bar: 100 mm. Values are mean 6 SEM of 5–6 animals. *p,0.05 vs control. {p,0.05 vs angiotensin II.
doi:10.1371/journal.pone.0041545.g008
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with the observation that various triterpenes have demonstrated
beneficial cardiac effects [27,28].
In the last years, galectin 3 has emerged as an important
mediator of cardiac remodeling in heart failure through its ability
to stimulate fibrosis, although its specific role and the factors
involved in its stimulation are under discussion. A recent study,
supporting its profibrotic role, has established a relationship
between serum galectin 3 and serum markers of cardiac
extracellular matrix turnover in heart failure patients [47]. The
present data show that angiotensin II is able to stimulate galectin 3
production in cardiac myofibroblasts, confirming previous data
that reported an increase in galectin 3 levels in left ventricle of
mice infused with a hypertensive dose of angiotensin II [48].
Moreover, in keeping with a preliminary report in which galectin 3
induced cardiac myofibroblast proliferation and collagen synthesis
[49], our data might suggest a role of galectin 3 in the profibrotic
effect induced by angiotensin II. This proposal is based on two
facts: First, the increase in collagen I induced by angiotensin II
paralleled an increase in protein levels of galectin 3; second, the
decrease in collagen I levels in the presence of either triterpene was
reflected with a reduction in galectin 3. This observation can be
relevant from the clinical point of view because it has reported that
galectin 3 levels are associated with adverse long-term cardiovas-
cular outcomes in patient with heart failure [17].
Our in vivo findings confirm the potential cardiac effects of the
natural triterpenes. Both inhibit left ventricle remodeling, hyper-
trophy and fibrosis in hearts from angiotensin II–infused mice.
This antifibrotic effect could be a direct effect of these triterpenes
because in cardiac myofibroblasts they restrain the production of
collagen I and profibrotic mediator galectin 3. They also inhibit
proliferation in cardiac myofibroblasts acting as PPAR-c modu-
lators. Given that pathological proliferation of cardiac myofibro-
blasts and the consequent extracellular matrix production are
important contributors to the adverse cardiac remodeling that
follows myocardial injury, our results suggest mechanisms by
which erythrodiol and uvaol might exert beneficial effects on this
process. In addition, these beneficial effects can be extended to
other situations such as hypertension if we consider the important
role of ventricular remodeling in the deterioration of cardiac
function and the evolution to heart failure. Although we have
reported potential signalling pathways that can be modulated by
triterpenes, the study cannot clarify the effect of either erythrodiol
or uvaol on the sequential activation or inhibition of the
mentioned key signaling factors. However, the potential relevance
of the triterpenes activity certainly deserves a further, but
independent, study directed towards obtaining a better under-
standing of the downstream cascades and molecular mechanisms
underlying their actions on cardiac fibroblast functions.
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Figure 9. Effect of erythrodiol and uvaol on and left ventricle
remodeling and serum BNP levels induced by angiotensin II on
mice. Mice infused with angiotensin II (Ang II; 1.44 mg Kg21 day21)
were treated with erythrodiol (ERY; 50 mg Kg21 day21) or uvaol (UVA;
50 mg Kg21 day21) for two weeks. Left ventricular cross sectional area
(LVCSA, A) and left ventricular wall thickness (LVWT, B) were measured
in Masson’s trichrome stained sections. Two-three sections for each
animal at the midregion area were analysed. Magnification 5X. Serum
BNP levels were assessed by using a mouse BNP-specific ELISA (C).
Values are mean 6 SEM of 5–6 animals. *p,0.05 vs control. {p,0.05 vs
angiotensin II.
doi:10.1371/journal.pone.0041545.g009
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